Skip to NavigationSkip to content

Top Ten most popular articles on this week

Published on 06/10/17 at 10:21am

The week has flown by and was packed with a number of shocking stories. With the ongoing uncertainty regarding Brexit, AstraZeneca Chairman Leif Johannson has revealed that his company believes a three-year transition period would be the best course of action.

In France, police have raided Merck KGaA's top office in the country over a scandal regarding the German manufacturer's thyroid treatment Levothyrox. And, perhaps most disturbingly, new research has indicated that more than half of all cancer drugs approved by the EMA actually present no clinical benefits.

Check out the week's ten most popular articles on now!

10. CureTech reclaims rare disease drug from Pfizer for $20 million

CureTech, a biotech firm owned by Clal Biotechnology Industries, is set to reclaim a drug it sold more than two years ago, paying $20 million to Pfizer for pidilizumab, a treatment for diffuse intrinsic pontine glioma (DIPG).

9. AbbVie adds biologic production capability to Singapore facility

Abbvie has expanded the operational capability of its facility located at the Tuas Biomedical Park in Singapore with the addition of a biologics manufacturing facility.

8. AstraZeneca Chairman wants three-year Brexit transition period

The Chairman of AstraZeneca, Leif Johansson, revealed in no uncertain terms that his company would like there to be a three-year Brexit transition period.

7. MSD pulls out of hep C space to Gilead’s relief

MSD, known as Merck in North America, has announced that it will curtail its attempts to make an impact in the hepatitis C space, citing a crowded marketplace as its reason.          

6. Collaboration brings forward potential broad flu cure

A joint research effort between The Scripps Research Institute and Janssen has seen the development of a peptide that could be effective against most strains of flu.

5. Overcoming real-world challenges to maximise the benefit of treatment for patients with multiple myeloma

Dr Antonio Palumbo, Distinguished Research Fellow Oncology, Takeda Pharmaceuticals addresses how far we’ve come in treating multiple myeloma, and how far we still have to go.

4. Five more biosimilar-free years for AbbVie’s megablockbuster

After a financial deal was agreed with Amgen, it looks like AbbVie's Humira should have the immediate biosimilar threat removed from its path running up to the beginning of 2023.

3. Could the new EU Medical Devices Regulation put the UK MedTech industry in peril?

Gill Jennings and Every's Fiona Stevens discusses recent developments in medical devices regulation and the subsequent impact on IP and investment in the medtech sector.      

2. 57% of cancer drugs uses approved by EMA show no benefit

A new study conducted by King’s College London and LSE has found that half of all treatments approved by the EMA failed to show clinical benefit.

1. Police raid French HQ of Merck KGaA over thyroid drug scandal

Police have raided the French headquarters of German drug manufacturer Merck KGaA over a scandal concerning its thyroid treatment Levothyrox.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches